Text Size

Tracking Progression of Amyotrophic Lateral Sclerosis

This study is not yet open for participant recruitment.
Verified January 2012 by University of Miami
Sponsor:
Information provided by (Responsible Party):
Michael Benatar, University of Miami
ClinicalTrials.gov Identifier:
NCT01508962
First received: January 9, 2012
Last updated: January 11, 2012
Last verified: January 2012
History of Changes
  Purpose

The goal of TRACK-ALS is to systematically study the onset and progression of ALS.


Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Miami:

Groups/Cohorts
Pre-symptomatic people at genetic risk for ALS
Individuals affected with ALS

  Eligibility

Ages Eligible for Study:   18 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

People affected with ALS and people at genetic risk for developing ALS.

Criteria

Inclusion Criteria:

  • Affected with ALS
  • At risk for ALS
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01508962

Locations
United States, Florida
University of Miami Not yet recruiting
Miami, Florida, United States, 33136
Contact: Michael Benatar, MD, PhD            
Sponsors and Collaborators
University of Miami
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Michael Benatar, Associate Professor of Neurology, University of Miami
ClinicalTrials.gov Identifier: NCT01508962     History of Changes
Other Study ID Numbers: TRACK-ALS
Study First Received: January 9, 2012
Last Updated: January 11, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Miami:
Disease onset
Disease progression

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
 Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013